Importance of Immunization and Immunization Registries by Blevins, Jason
IMPORTANCE OF IMMUNIZATION AND IMMUNIZATION REGISTRIES 
By 
Jason Blevins 
A Master's Paper submitted to the faculty of 
the University ofNorth Carolina at Chapel Hill 
In partial fulfillment of the requirements for 
the degree of Master of Public Health in 
the Public Health Leadership Program. 
Chapel Hill 
Spring 2010 
ii 
 
 
 
 
 
 
Abstract 
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(Under the direction of Lori Evarts) 
 
 
 Abstract:  Healthy People 2010 has an important goal of having 95% of children 
enrolled in an immunization registry by age two.  This paper examines the importance of 
vaccines, safety issues with vaccines, the importance of having a useful immunization 
registry, benefits and current limitations of vaccine registries, as well as suggestions on how 
to improve current registries, including how to ensure future expandability and usefulness.  I 
conducted a meta-analysis of existing research on the topic of immunization registries, 
vaccine importance, and vaccine safety, as well as used my own practicum experience 
implementing the North Carolina Immunization Registry into hospital nurseries across the 
state. My research found that while immunization registry use has increased dramatically 
within the past decade, there are still stumbling blocks and problems that need to be 
addressed, but the benefits of a working registry greatly outweigh any limitations.  Finally, I 
offer suggestions of how some of the major limitations can be addressed. 
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INTRODUCTION 
Although Edward Jenner’s work Variolae Vaccinae in 1798 is credited with being the 
first scientifically sound reasoning to vaccinate based on his experiments using cowpox to 
protect against smallpox, the idea for vaccination came much earlier.  One of the earliest 
recorded attempts at inducing immunity comes from seventh century Indian Buddhist monks, 
who ingested snake venom in an attempt to become immune to its effects.  (S. L. Plotkin & 
Plotkin, 1999)  Unverified reports come from as early as the tenth century about smallpox 
variolation in China, but the earliest substantiated report comes from 1695 where a Chinese 
medical text entitled The Golden Mirror of Medicine described ways to inoculate against 
smallpox, the most common method being plugging the nose with powdered scabs taken 
from someone suffering from smallpox.  (S. L. Plotkin & Plotkin, 1999) 
 From these humble beginnings, all the way to the advent of DNA-recombinant 
vaccines,  (S. L. Plotkin & Plotkin, 1999) vaccination has gone from being something that 
was initially an observation made into life-saving science, now appreciated and required by 
people in order to preserve health and reduce mortality. Vaccine administration can become 
more efficient and effective through use of immunization registries. 
 
OVERVIEW OF VACCINES AND RECOMMENDATIONS IN THE UNITED 
STATES 
 Babies, the world’s most precious and vulnerable population, require special scrutiny 
and care in order to protect them from diseases that can be especially harmful or fatal, given 
their immature immune system.  In the United States, the Department of Health and Human 
Services (DHHS) and the Centers for Disease Control and Prevention (CDC) have adopted a 
schedule of recommended vaccinations for babies, which have been created by the Advisory 
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Committee on Immunization Practices (ACIP) and approved by the American Academy of 
Pediatrics (AAP), the American Academy of Family Physicians (AAFP), and ACIP as shown 
in Table 1.  (Centers for Disease Control and Prevention, 2010c)  While these vaccinations 
are “recommended” instead of “required”, it is worth noting that child care facilities, schools, 
colleges, and universities require proof of vaccination before admittance in North Carolina.  
(North Carolina Department of Health and Human Services, 2010c) 
 
Table 1:  2010 Recommended immunizations for babies 
a:  combined vaccine effective against diphtheria, tetanus, and pertussis.  b: pneumococcal disease 
vaccine c:  Haemophilius influenzae Type b vaccine   d:  Rotavirus vaccine e:  Annual seasonal influenza 
vaccine recommended at 6 months-18 years, including 2009 H1N1 vaccine f:  Measles, mumps, and 
rubella vaccine.    
Adapted from the U.S. Department of Health and Human Services and Centers for Disease Control and 
Prevention 2010 Child & Adolescent Immunization Schedule 
 
 The first Hepatitis B vaccine, created from purified antigens taken from the blood 
plasma of infected persons, was introduced in 1981.  While both safe and effective, the 
vaccine was not well received from the public due to fears of infection from other blood 
borne diseases, most notably from the newly discovered Human Immunodeficiency Virus 
(HIV).  (Atkinson, Wolfe, Hamborsky, & McIntyre, 2009)  A recombinant DNA vaccine, 
made by cloning Hepatitis B antigens in yeast, was introduced in 1986.  This newer vaccine 
had no risk of infection with Hepatitis B, HIV, or any other blood borne disease.  (Atkinson 
et al., 2009)  This newer vaccine was well-received and was integrated into the 
immunizations of babies labeled as high-risk, due to ethnicity, mother’s status, or potential 
for exposure in the home.  (Mahoney & Kane, 1999)  Cost-effectiveness analyses were done 
Age (in months) Recommended Immunizations 
0 (birth) Hepatitis B 
2 Hepatitis B (at 1-2 months), DTaP
a
, PCV
b
, Hib
c
, Polio, RV
d
 
4 DTaP, PCV, Hib, Polio, RV 
6 Hepatitis B (at 6-18 months), DTaP, PCV, HiB, Polio (6-18 months), RV, Influenza
e
 
12 MMR
f 
(12-15 months), PCV (12-15 months), Hib (12-15 months), Varicella (12-15 
months), Hepatitis A (12-23 months), Influenza 
15 DTaP (15-18 months), Influenza 
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and, when coupled with production advancements in vaccine manufacture, data showed that 
all babies would benefit from vaccination.  (Mahoney & Kane, 1999)  By 1997, more than 
80% of children between two and three years of age had received each of the three 
recommended doses of Hepatitis B vaccine.   (Mahoney & Kane, 1999) Between 1990 and 
2004, due in large part to the availability of the Hepatitis B vaccine, the all-population United 
States incidence of the disease decreased 75%, which included a 94% decline in incidence 
among children and adolescents. (Atkinson et al., 2009; Centers for Disease Control and 
Prevention, 2010c)(Atkinson et al., 2009; Centers for Disease Control and Prevention, 
2010c) 
 One-third of exposures to Hepatitis B in the United States are due to perinatal and 
early childhood exposures; further, 25% of infants who acquire Hepatitis B will die of either 
primary hepatocelluar carcinoma or cirrhosis. (Mahoney & Kane, 1999)  Also, Hepatitis B is 
seen as the second most preventable risk factor for cancer, behind tobacco use.  (Duclos, 
2003)  Consequently, Hepatitis B vaccination at birth is especially important.  If not treated 
with Hepatitis B vaccine, 70%-90% of babies born to women positive for Hepatitis B would 
become infected themselves.  In the United States, approximately 25,000 women positive for 
Hepatitis B give birth each year, and if not for immunotherapy after birth, 9,500 babies per 
year would be infected with Hepatitis B. (Mahoney & Kane, 1999)  The number of pregnant 
women with Hepatitis B in North Carolina was not available, although Hepatitis B testing for 
all pregnant women has been required since 1990.  (North Carolina Department of Health 
and Human Services, 2010a)  The CDC notes that the most commonly reported adverse 
events related to Hepatitis B vaccine administered to children are pain at the injection site 
(3%-9% of children) and systemic effects such as irritability, headache, and fatigue (0.4%-
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6.4% of children).  Serious systemic events and allergic reactions are rare.   (Centers for 
Disease Control and Prevention, 1999a)  The Hepatitis B vaccine has been alleged to be 
associated with serious adverse events, including development or worsening of Multiple 
Sclerosis, rheumatoid arthritis, diabetes, chronic fatigue syndrome, and lymphoblastic 
leukemia.  (Duclos, 2003) However, none of the associations have been verified, and an 
Institute of Medicine (IOM) committee has documented evidence favoring the rejection of an 
association between the Hepatitis B vaccine and Multiple Sclerosis.  (Duclos, 2003)  
 The diphtheria, tetanus, and acellular Pertussis (DTaP) vaccine has been in use since 
1981 in Japan, and the first DTaP vaccine was licensed for use in the United States in 1991.  
Previously, diphtheria, tetanus, and whole-cell Pertussis (DTP) vaccines had been in use, 
which contained active Bordatella pertussis bacteria and endotoxins produced by those 
bacteria.  (Edwards, Decker, & Mortimer, 1999)  Injection site reactions occurred in about 
half of all DTP administrations, and other adverse events, including fever, swelling, and pain 
were common.  (Atkinson et al., 2009)  Due to the common occurrence of local reactions, 
concerns about the use of non-purified bacteria, and demonstrated correlation of the vaccine 
with anaphylaxis, febrile seizures, acute encephalopathy, and hypotonic-hyporesponsive 
episodes, the whole-cell Pertussis vaccines are no longer in use in the United States.  
(Atkinson et al., 2009; Edwards et al., 1999) The most common adverse reactions from DTaP 
are fever, redness at the injection site, swelling, fussiness, and drowsiness.  DTaP overall has 
far fewer adverse reactions than does DTP.  (Edwards et al., 1999)  Studies have been 
conducted investigating links between DTaP vaccination and limb swelling and sudden 
infant death syndrome; however, there was no evidence that the correlations were either 
clinically or statistically significant. (Griffin, Ray, Livengood, & Schaffner, 1988; Hoffman 
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et al., 1987; Marshall, Gold, Gent, & et al, 2006; Sekaran & Edwards, 2006; Walker, Jick, 
Perera, & et al, 1987) 
 Current recommendations state that children should receive DTaP vaccine at two, 
four, six, and fifteen months of age, with a booster dose between the age of four and six years 
when the child enters school.  Another DTaP booster should be given between eleven and 
twelve years of age, with at least five years elapsing since the previous dose.  Then, a booster 
should be administered every ten years.(Centers for Disease Control and Prevention, 2010c)  
Atkinson provides interesting epidemiological data on diphtheria, Pertussis, and tetanus.  
Diphtheria is rare in the United States, with an average of two to three cases per year since 
1980.  The number of cases of Pertussis has been increasing since 1980, with 25,827 in 2004, 
twenty-four percent of which were in children under six months old. While tetanus is not 
contagious, vaccine is the preferred method of treatment due to the ineffectiveness of 
antibiotic prophylaxis, (Atkinson et al., 2009) thus making the DTaP vaccine all the more 
important. 
 The first pneumococcal vaccine was produced in the United States in 1977, with the 
first pneumococcal conjugate vaccine (PCV) following in 2000.  (Atkinson et al., 2009) The 
non-conjugate pneumococcal vaccine is not effective in children under two years of age. 
(Atkinson et al., 2009)  Before the development of the PCV, the non-conjugate vaccine was 
given to adults for the prevention of conditions caused by the Streptococcus pneumoniae 
bacterium, including pneumococcal pneumonia and invasive pneumococcal disease.  
(Fedson, Musher, & Eskola, 1999) In children, S. pneumoniae can cause otitis media, 
pneumococcal pneumonia, bacteremia, invasive pneumococcal disease, and is the leading 
cause of bacterial meningitis in children under five years of age.  (Atkinson et al., 2009; 
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Fedson et al., 1999)  Prior to the adoption of PCV, over five million cases of otitis media in 
children under five years of age were reported per year in the United States, along with 
significant numbers of cases of bacteremia and pneumococcal pneumonia.  (Atkinson et al., 
2009)  Along with reducing the burden of disease in young children, PCV use is growing in 
importance due to growing the growing resistance of S. pneumoniae to penicillin.  (Fedson et 
al., 1999) 
 Current recommendations are for children to receive PCV at two, four, and six 
months of age, with a booster dose at twelve to fifteen months of age.  (Atkinson et al., 2009)  
Overall adverse reactions to PCV are lower than to non-conjugate vaccine, but Fedson noted 
that fever and pain are more common in those receiving PCV.   To date, no serious adverse 
reactions have been correlated with PCV, though a temporary increase in the viral load of 
HIV patients has been noted.  (Fedson et al., 1999) 
 The Haemophilus influenzae type b (Hib) vaccine was first used in the United States 
in 1985, with a Hib conjugate vaccine introduced two years later.  (Ward & Zangwill, 1999)  
Hib infections generally affect children under five years of age.  Most unvaccinated children 
have immunity to Hib by the time they are five years old due to having an asymptomatic 
infection.  (Atkinson et al., 2009)  Until 1992, Hib was the leading cause of bacterial 
meningitis in children, and also caused epiglottitis, pneumonia, arthritis, and cellulitis.  
(Atkinson et al., 2009; Ward & Zangwill, 1999) 
 Adverse reactions to the Hib vaccine are rare, with the most commonly reported 
reactions being injection site swelling, redness, and pain; fever is reported infrequently.  
(Atkinson et al., 2009) Recent research suggests that these adverse events may actually be in 
fact reactions to the DTaP vaccine, which is commonly administered concurrently with the 
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Hib vaccine.  (Atkinson et al., 2009)  No serious adverse events have been reported with Hib 
vaccination.  (Ward & Zangwill, 1999) 
 The first vaccine for polio was famously introduced in 1955 by Dr. Jonas Salk.  
Salk’s vaccine used an inactivated form of the poliovirus but contained only one serotype of 
poliovirus, while Dr. Albert Sabin’s 1963 oral vaccine contained attenuated versions of all 
three known serotypes of poliovirus.  (Sutter, Cochi, & Melnick, 1999)  The polio vaccine 
has been extremely effective in the United States.  From a high of 21,000 paralytic cases in 
1952, the last known case of wild virus acquired polio, which is where a person becomes 
infected with polio from a strain of poliovirus circulating in the environment rather than from 
a vaccine strain, was reported in the United States in 1979.  (Atkinson et al., 2009) 
 Since 1988, the polio vaccine currently in use in the United States is an enhanced-
potency inactivated poliovirus vaccine.  The attenuated oral poliovirus vaccine was 
discontinued from use in the United States in 2000, due in part to the fact that eight to ten 
persons per year were acquiring polio due to immune dysfunction or a mutation that made 
the previously attenuated poliovirus virulent.  (Atkinson et al., 2009) 
 Current recommendations are for children to get poliovirus vaccines at two and four 
months of age, between six and eighteen months of age, and a booster before beginning 
school, usually between four and six years of age.  If necessary, the series of four 
immunizations can be accelerated to receive all four within an eighteen week period, but that 
is only necessary in the few countries where wild poliovirus is still endemic.  (Atkinson et 
al., 2009)   Perhaps the most well-known to reaction to poliovirus vaccination is known as 
the Cutter incident.  In 1955, 204 cases of polio developed as a result of improperly 
attenuated vaccine.  Stricter safety measures were implemented after the incident, and the 
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poliovirus vaccine used today is very safe.  (S. A. Plotkin, Murdin, & Vidor, 1999)  Adverse 
reactions to current poliovirus vaccinations are minor and include pain and redness at the 
injection site.   Since the inactivated poliovirus vaccine contains trace amounts of the 
antibiotics streptomycin, polymyxin B, and neomycin, the potential for an allergic reaction to 
these ingredients exist, but has not been documented.  (Atkinson et al., 2009; S. A. Plotkin et 
al., 1999)  Guillain-Barré syndrome was suspected as a potential adverse event related to 
poliovirus vaccination, but research has been able to determine neither clinical nor statistical 
significance.  (S. A. Plotkin et al., 1999; Souayah, Nasar, Suri, & Qureshi, 2009) 
 The first rotavirus (RV) vaccine was introduced in 1998, but withdrawn in 1999 due 
to intestinal complications, most namely intussusceptions.  A second, safer vaccine was 
introduced in 2006.  (Atkinson et al., 2009)   If every child under five years of age were 
vaccinated for RV, 500,000 physician visits, 50,000 hospital visits, and 20-40 deaths per year 
would be prevented in the United States.  (Clark, Glass, & Offit, 1999)  RVs are associated 
with dehydration and diarrhea in children, and by age three, virtually all children worldwide 
have been infected by a variant of RV, even in developed countries with high standards of 
sanitation.  (Clark et al., 1999) 
 Recommendations for RV vaccination include two or three doses, spaced one or two 
months apart, beginning at an age of two months.  (Atkinson et al., 2009)  Adverse reactions 
among infant recipients of RV vaccine were rare, but adverse events included 
intussusceptions, vomiting, diarrhea, irritability, and fever.  No serious adverse events have 
been reported.  (Atkinson et al., 2009) 
 The first modern influenza vaccine was produced in 1971 and is one of the first 
examples of a recombinant vaccine, which is where the virus can be taken from humans and 
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be mass-produced.  (Kilbourne & Arden, 1999)  This is especially useful in influenza 
vaccines due to the difference in predominant viruses from year to year.  While children are 
not usually at risk for complications from influenza, they are a major factor in the 
transmission of the virus.  Interruption of the spread of the virus in children could lead to a 
real decrease in community influenza rates.  (Atkinson et al., 2009)     
 Influenza vaccination is recommended yearly for infants.  If an infant received two 
doses of influenza in the previous season, only one dose is indicated in the current season.  
(Atkinson et al., 2009)   Influenza vaccines are generally safe, with pain, tenderness, and 
itching sometimes developing at the injection site, with fever, chills, and allergic reactions 
occurring rarely after influenza vaccine administration.  (Atkinson et al., 2009; Kilbourne & 
Arden, 1999) 
 The first measles vaccines were introduced in 1963, the mumps vaccine was first 
introduced in 1967, and the rubella vaccine was first introduced in 1969.  (Atkinson et al., 
2009)  The combination measles, mumps, and rubella (MMR) vaccine was first introduced in 
the United States in 1971 and has become the preferred method of MMR combination 
vaccination.  (Redd, Markowitz, & Katz, 1999)  As reported by Atkinson, in the United 
States, rubella cases reached a peak of 57,686 cases in 1969, declining to only seven cases in 
2003.  Measles cases declined rapidly after the introduction of the vaccine, from 
approximately 500,000 cases per year prior to vaccine availability, to a low of 37 cases 
reported in 2004.  However, between the years of 1989 and 1991, there was a dramatic 
increase in the number of measles cases, with a total of 55,622 cases reported in that three 
year period, with blame being placed on low vaccination coverage.  The incidence of mumps 
has also steadily declined since introduction of the vaccine, with 212,000 cases reported in 
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1964 and only 258 cases in 2004.  There were spikes in the number of cases of mumps in 
1987 (12,848 cases) and 2006 (6,000 cases) which were attributed to a faulty vaccine.  
(Atkinson et al., 2009) 
 Guidelines recommend that children receive doses of MMR vaccine between twelve 
and fifteen months of age and a follow-up dose before entering school.  (Atkinson et al., 
2009; Centers for Disease Control and Prevention, 2010c)  MMR vaccine has few adverse 
events with the most common being fever, rash, and joint pain.  Rare cases of central nervous 
system dysfunction have been reported.  Correlation of MMR vaccine with Guillain-Barré 
syndrome has been discounted, and the IOM has found no evidence linking MMR 
vaccination with thrombocytopenia or anaphylaxis,  (Redd et al., 1999)  Studies linking 
MMR vaccination with autism have been discounted for lack of evidence.  (W. Chen, 
Landau, Sham, & Fombonne, 2004; Peltola et al., 1998; Taylor, Miller, Farrington, & et al, 
1999) 
 Varicella vaccine is a live, attenuated vaccine that has been in use in Japan since the 
1970s, and first became licensed for use in the United States in 1995.    Prior to vaccine 
availability, there were approximately four million cases of varicella per year.  The number 
of annual cases dropped 93% by 2006. (Atkinson et al., 2009)  While disease caused by 
varicella is generally not fatal in children, if the disease is contracted in adulthood, the case-
fatality rate is 25 times greater than if the disease were contracted as a child.  Disruption of 
the transmission cycle between children and adults, coupled with an estimated $6.6 million 
costs savings from varicella vaccinations, mainly due to less work lost by parents caring for 
sick children, make varicella vaccination both important for preventing disease as well as 
very cost effective.  (Gershon, Takahashi, & White, 1999)   
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 Current guidelines recommend administration of one dose varicella vaccine for 
children between twelve and fifteen months of age, with a booster dose before beginning 
school, with a minimum of three years between doses.  (Atkinson et al., 2009; Centers for 
Disease Control and Prevention, 2010c)  The vaccine is safe, with the most common adverse 
events being injection site reactions such as pain or redness.  Since the varicella vaccine does 
contain live virus, there is a risk of transmission infection in immunocompromised persons, 
including pregnant women, and mild Herpes zoster infection has also been reported in rare 
cases.  (Atkinson et al., 2009; Gershon et al., 1999) However, varicella vaccine efficacy can 
be as low as 70%.  (Atkinson et al., 2009) 
 The first Hepatitis A vaccine was licensed for use in the United States in 1995.  The 
incidence of Hepatitis A is low in the United States when compared to other endemic areas 
such as Central and South America, Africa, the Middle East, Asia, and the Western Pacific; 
however, there are cyclical epidemics of Hepatitis A that occur approximately every ten 
years in the United States.  (Atkinson et al., 2009)  The most commonly reported method of 
exposure in the United States is contact with an infected household member.  Children, who 
are generally asymptomatic when infected with Hepatitis A, can be a major source of 
potential infections if not vaccinated. (Hall, Kane, Roure, & Meheus, 1999) The number of 
Hepatitis A infections peaked in the United States in 1971 with 59,606 cases, declining to 
2,974 cases in 2007, most of which were in children older than two years of age.  (Atkinson 
et al., 2009) 
 Current guidelines recommend a dose of Hepatitis A vaccine between twelve and 23 
months of age.  (Atkinson et al., 2009; Centers for Disease Control and Prevention, 2010c) 
Adverse events from Hepatitis A vaccination are generally rare, and mainly include injection 
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site reactions.   Diarrhea, fever, headache, and vomiting occur rarely.  More serious adverse 
events such as syncope, jaundice, and convulsions have been reported, but no evidence to 
indicate clinical or statistical significance has been shown.  (Atkinson et al., 2009; Feinstone 
& Gust, 1999) 
 
VACCINE EFFICACY 
Vaccination has been heralded as number one of the top ten public health 
achievements of the twentieth century (Centers for Disease Control and Prevention, 1999b), 
being second throughout history only to the availability of clean water as the greatest 
contributor to mortality reduction and population growth for the world’s people.  Not even 
the availability of antibiotics has had as profound an effect on the health of the world.  (S. L. 
Plotkin & Plotkin, 1999)  Due to advances in vaccines and the benefits of keeping diseases 
under control, it is now more important than ever to make sure that as many people as 
possible receive all necessary vaccines.  Immunization information systems, or immunization 
registries, can help keep track of vaccinations and schedules in an increasingly mobile 
society.   Enrolling infants at birth into an immunization registry provides the best 
opportunity to provide maximum benefit to both society and the individual. 
Examination of the present incidence of vaccine-preventable infectious disease is the 
optimal method to evaluate the value of vaccination.  Each infectious disease has a basic 
reproductive rate, R0.  R0 can be explained as the number of cases of secondary disease 
caused by each case of a disease in a population where everyone is susceptible to the disease, 
meaning no immunity from vaccine or previous disease.  R0 is calculated for a disease for a 
specific population, taking into account factors such as birth rate, age distribution, and 
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average age of infection.  (Anderson & May, 1985) Using R0, one can quickly calculate the 
impact of vaccinations using a simple model: Rt=R0(S/N).  Rt is the effective reproductive 
number, which is the true transmission rate of the disease as affected by persons who are 
immune, dead, or otherwise taken out of the susceptible population.  S represents the number 
of susceptible persons left in the population, and N represents the total population.  By 
decreasing S through vaccination, Rt can be reduced below one, meaning that the disease will 
not spread in this population.    This model assumes homogenous mixing within a population 
– meaning that every person in the population has an equal chance of coming into contact 
with every other person and that that everyone is fully susceptible.   This, of course, would 
never happen in nature, but is useful for demonstrating the quick spread of infectious disease 
and the effectiveness of vaccines.  (Scherer & McLean, 2002)  Table 2 presents the R0 of 
several common vaccine-preventable infectious diseases, and the critical vaccination  
percentages (S/N) needed to inhibit spread of the disease.  (Anderson, 1992) 
Table 2:  R0 and critical vaccination percentages to inhibit disease spread 
 
 
 
 
 
        
Adapted from Anderson, 1992. 
 
From the table above, one can see that both measles and Pertussis each have a high R0 of 15-
17.  This means that every case of disease will cause 15-17 new cases of disease, and each of 
those new cases will each cause 15-17 new cases, and so on, thus propagating into an 
epidemic, where there is a far greater number of cases of a disease in a population than 
normal (Last, 2007), based on a simple population system as described above.  Fortunately, 
Disease Basic Reproductive Rate (R0) Critical Vaccination Percentage (S/N) 
Measles 15-17 92-95 
Pertussis 15-17 92-95 
Mumps 10-12 90-92 
Rubella 7-8 85-87 
Diphtheria 5-6 80-85 
Polio 5-6 80-85 
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the phenomenon of herd immunity is at work in populations, whereby some protection from 
disease is given to persons who may otherwise be susceptible due to the fact that most of the 
population is not susceptible to infection due to vaccination or other immunity. (Anderson & 
May, 1985)  Scherer and McLean provide a formula that demonstrates the effectiveness of 
varying levels of vaccination, with the caveat that the model assumes perfect, lifelong 
immunity. (Scherer & McLean, 2002)  Again, this would not happen in practice, but does 
provide a rough goal for immunization.  Table 3 demonstrates the effect of varying levels of 
vaccination on the R0 of measles, and the number of required child vaccinations in two 
hypothetical cities with 20,000 and 100,000 children.   
Table 3:  Transmission dynamics for measles affected by vaccination 
 
 
As can be seen in the table above, between 95% to 100% of a population’s children would 
have to be vaccinated, or otherwise not susceptible to measles, in order to halt the spread of 
the disease.   Continued vigilance, not just a one-time mass vaccination campaign would be 
required to maintain control, since the susceptible population is dynamic due to births, 
deaths, infection, vaccination, and population movement in and out of an area. (Anderson & 
May, 1985)  For diseases with smaller R0, such as polio, the critical vaccination percentage is 
much lower due to the fact that each primary case spawns fewer secondary cases, thus 
allowing R0 to fall below one at a lower level of population non-susceptibility.  (Scherer & 
% Vaccinated Basic Reproductive 
Rate (R0) 
# Vaccines required for a 
population of 20,000 children 
# Vaccines required for a 
population of 100,000 
children 
0 15-17 0 0 
25 11.25-12.75 5,000 25,000 
50 7.5-8.5 10,000 50,000 
75 3.75-4.25 15,000 75,000 
               95 0.75-0.85 19,000 95,000 
100 0 20,000 100,000 
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McLean, 2002)  The R0 of a disease can fall below one without the entire population being 
immune, thus allowing control, due to herd immunity. 
Mixing of the population is required for transmission of infectious disease. Therefore, 
a population with enough non-susceptibles (such that Rt falls below one), transmission of a 
disease can halt since a susceptible person’s likelihood of being exposed to the disease is low 
due to the decreased chance of mixing with carriers since so much of the population is not 
susceptible.   However, persons should be educated to not rely on herd immunity, since if too 
many people assume they will be protected by herd immunity and do not receive a 
vaccination, the susceptible population may be large enough to allow the disease to become 
an epidemic.  
 
VACCINE SAFETY CONCERNS 
 While vaccines provide an invaluable service to society, there is a heightened 
expectation of their safety, especially in children.  (R. T. Chen, Davis, & Sheedy, 2004)   
Any adverse events related to vaccines must be minimal to ensure compliance and use.  
Additionally, children have the decision to get vaccinated made for them, either by their 
parents or the government.  There have been numerous reports and studies completed to 
explore the adverse events of vaccination, including allergic reactions (Offit & Hackett, 
2003), sudden infant death syndrome (Vennermann, Butterfass-Bahloul, Jorch, & et al, 
2007), Guillain-Barré syndrome (Souayah et al., 2009), Multiple Sclerosis, (Demicheli, 
Rivetti, Di Pietrantonj, Clements, & Jefferson, 2003) thrombocytopenia, (Rajantie, Zeller,  
Treutiger, & Rosthoj, 2007) and autism (Honda, Shimizu, & Rutter, 2005).  Though little or 
no evidence has been found linking vaccination with any of these serious adverse events, it is 
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still of concern to both parents and medical practitioners.  Recent news has revealed that 
Wakefield’s 1998 study that first linked vaccination to autism, published in The Lancet, used 
falsified data and was retracted.  (Triggle, 2010)  The concern for adverse events comes from 
both the immunologic reaction that vaccines cause and the additives used in vaccines.  The 
additives, namely thimerosal, aluminum hydroxide, and mercury, have been identified as 
potential catalysts for many of the adverse events purported to be caused by vaccines, most 
famously autism. (Ball, Ball, & Pratt, 2001; Gherardi, Coquet, Cherin, & et al, 2001; 
Pichichero, Cernichiari, Lopreiato, & Treanor, 2002; Stehr-Green, Tull, Stellfeld, Mortenson, 
& Simpson, 2003)  
 Thimerosal is a mercury-containing organic compound used to prevent microbial 
contamination of vaccines. Thimerosal has been either removed completely from or reduced 
to trace amounts in all vaccines for children, with the exception of the influenza vaccine. 
(United States Food and Drug Administration, 2010) Although FDA found that no harm was 
done by thimerosal in vaccines, it was recommended that thimerosal be removed from 
vaccines as a precaution due to parental concerns of the purported link between mercury, 
thimerosal, and autism. (United States Food and Drug Administration, 2010) 
 Aluminum hydroxide is currently used as an adjuvant in the hepatitis A, hepatitis B, 
DTaP, and Hib vaccines.  (Centers for Disease Control and Prevention, 2010b)  Although 
there were concerns that aluminum-containing vaccine additives could cause conditions such 
as macrophagic myofasciitis, studies have confirmed both the safety and efficacy of 
aluminum hydroxide use in vaccines. (Centers for Disease Control and Prevention, 2010b; 
Gherardi et al., 2001)  
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 Due to the potential for adverse events, an infrastructure was established in the United 
States specifically for monitoring vaccine safety and reporting any adverse events.  The 
Vaccine Safety Datalink project is a joint venture between the CDC and eight managed care 
organizations (MCOs), allowing data that includes both vaccination information and medical 
outcomes to be collected and analyzed by the CDC.  (DeStefano & Vaccine Safety Datalink 
Research Group, 2001) The MCOs involved in the collaboration are: Group Health 
Cooperative of Puget Sound in Seattle, Washington; Kaiser Permanente Northwest in 
Portland, Oregon; Kaiser Permanente Medical Care Program of Northern California in 
Oakland, California; Southern California Kaiser Permanente Health Care Program in Los 
Angeles, California;  HealthPartners Research Foundation in Minneapolis, Minnesota; 
Marshfield Clinic Research Foundation in Marshfield, Wisconsin; Kaiser Permanente 
Colorado in Denver, Colorado; and Harvard Pilgrim Health Care in Boston, Massachusetts. 
(Centers for Disease Control and Prevention, 2010d) The Vaccine Adverse Event Reporting 
System (VAERS) is a product of the collaboration between the CDC and the Food and Drug 
Administration (FDA).  It is a passive system, meaning that reports of adverse events must be 
reported by vaccine manufacturers, parents, patients, or health care providers. (Zhou, Pool, 
Iskander, & et al, 2003)  Since 1990, VAERS has received over 200,000 adverse event 
reports, and currently receives about 30,000 adverse event reports annually, with thirteen 
percent of those reports being serious.  (Centers for Disease Control and Prevention, 2010a) 
 
NEED FOR IMMUNIZATION REGISTRIES 
 Due to the large number of recommended vaccines for infants, which total greater 
than twenty by the age of fifteen months (Centers for Disease Control and Prevention, 
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2010c), the need for immunization registries is greater than ever.  Data show that providers 
often overestimate the percentage of their patients that are fully vaccinated  (Linkins, 2001) 
due to:  not being able to easily access the information; parents often do not know the 
immunization status of their children; most providers not using an immunization registry do 
not send out immunization reminders to their patients; and that by age two, twenty percent of 
children have been seen by more than one medical provider, not counting the hospital in 
which they were born. (Linkins & Feikema, 1998)  Due to these issues, vaccination benefits, 
and the setting of a Healthy People 2010 goal of having greater than 95% of children under 
six years of age enrolled in an immunization registry (Centers for Disease Control and 
Prevention, 2006), the Robert Wood Johnson Foundation and the National Immunization 
Program (NIP) of the CDC initiated funding programs to facilitate the introduction of 
immunization registries.  Starting in 1991, the All Kids Count Project (AKC) of the Robert 
Wood Johnson Foundation, in conjunction with other private foundations, funded 24 vaccine 
registry projects.  NIP awarded $42.5 million to 64 registry sites in 1996 alone.  (Linkins, 
2001)   
 
CURRENT STATUS OF IMMUNIZATION REGISTRIES 
All 50 states, six individual cities, and three United States territories received either 
AKC or NIP funding and have either built or are building Healthy People 2010 compliant 
immunization registries.  (Linkins, 2001) However, recent federal and state budgets have 
limited the amount of startup funding available to state and local immunization registries.  A 
few states, including Washington and Oregon, have entered into agreements with local health 
19 
 
management organizations (HMOs) to secure continued funding for their registries. (Linkins, 
2001) 
 In 1997, NIP conducted surveys of the registry site funding grantees to compile a list 
of what registry administrators consider core functions of an immunization registry.  Table 4 
summarizes the core functions, in order of descending importance as judged by the registry 
administrators. (Linkins, 2001) 
Table 4:  Core Functions of Immunization Registries as Described by Registry Managers 
Core Function Percent of Administrators who 
Listed as Core Function 
Consolidate medical records from multiple health providers 93 
Store data 91 
Automatically retrieve birth data 91 
Allow electronic retrieval of information on demand 91 
Perform error checking upon data entry 91 
Ensure privacy, security and confidentiality 90 
Share records with other providers/systems 87 
Calculate required vaccines for patients based on history 85 
Produce official immunization records 85 
Identify patients late for immunization 84 
Electronic submission of immunization information at point of care 81 
Detection of duplicate records in the system 75 
Production of immunization coverage reports 75 
Adapted from Linkins, 2001 
Of note, sixteen percent of administrators named adverse event reporting as a core 
function, and thirteen percent named vaccine inventory management as a core function.  
(Linkins, 2001) Having vaccine inventory management as a low priority was somewhat 
surprising, since this feature would be complementary to other practice time-saving features 
such as:  record consolidation, electronic information retrieval, and patient reminder 
generation.  The inventory management feature would be easy to implement and maintain, 
since it could be implemented by the registry administrator, potentially using CDC source 
code, and given to all participating sites at once by adding the vaccine management system to 
the existing immunization registry.   
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 In 2000, 21% of children had at least two immunizations entered in an immunization 
registry. Twenty-six states, four cities, and two United States territories had operational 
registries covering their entire target areas, and the rest of the states’ registries were either 
partially up and running or being developed. (Saarlas, Edwards, Wild, & Richmond, 2003) 
By 2005, 56% of children nationwide were enrolled in an immunization registry, and by 
2006, the percentage increased to 65%. (Urquhart, Rasulnia, & Kelly, 2008) 
 Even after successful implementation of an immunization registry, there is still much 
work to be done.  Specifically, registries must remain current and compatible with relevant 
technologies, consider full integration with electronic medical records systems, be dynamic 
for future updates such as immunization recommendation changes, and perhaps most 
importantly, be able to communicate with other registry systems and databases.  Due to 
children seeing different providers and moving from one immunization registry target area to 
another, it is vital for inter-system communication to become the norm so that the efficacy of 
the registries are not lost.  Interfacing with other databases will continue to be important to 
ensure complete coverage, such as automatic importing of birth records, targeting high-risk 
or underserved populations, and linking with external federal data.  NIP allotted $1 million in 
funding to link the Special Supplemental Nutrition Program for Women, Infants, and 
Children (WIC) (Linkins, 2001), and linking registry systems to Medicaid data will become 
more important as more Medicaid recipients receive their immunizations at private providers 
rather than at local health departments. 
 Nationally, progress in the development and adoption of immunization registries has 
increased greatly since 1999, and toward the Healthy People 2010 goals.  For instance, the 
Wisconsin Immunization Registry, in use since 1999, had a statewide completeness rate of 
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64% in 2008, an increase of six percent from the previous year, with over six million client 
records.  (Schauer et al., 2009)  It was in use by 15,000 persons, 1,200 organizations, and 
3,500 facilities. It is estimated that 77% of providers statewide are using the system. (Schauer 
et al., 2009)  This is similar to the national average of 65% completeness, even though ten 
registry sites reported completeness rates of 81%-94%. (Urquhart et al., 2008)  The North 
Carolina Immunization Registry (NCIR) is in use by all of North Carolina’s public health 
departments, as well as 600 private practices which account for more than 50% of providers 
in the state. (North Carolina Department of Health and Human Services, 2010b)  The NCIR 
is currently being integrated into hospital neonatal care units across the state.  In the city of 
Philadelphia, this immunization registry, which is populated from city birth records, 92% of 
children were found to be entered; however significant difference in vaccination coverage 
rates were found when data from the immunization registry were compared to patient’s paper 
records kept at providers’ offices. (Kolasa, Chilkatowsky, Clarke, & Lutz, 2006) 
 
BENEFITS OF IMMUNIZATION REGISTRY USE 
 With widespread adoption of immunization registries, many realize benefits from 
their widespread implementation.  Health care providers such as physicians and nurses, office 
managers, parents, patients, and society at large all benefit from having a functional 
immunization registry.  Many benefits of immunization registries have already been realized, 
including reduced extra immunization, which could lead to fewer reactions and adverse 
events and less wasted vaccine.  (Kempe, Steiner, Renfew, & et al, 2001)  Use of an 
immunization registry can lead to reduced costs and staff time for practices by: providing 
vaccine inventory management assistance; integrating into billing software; quickly 
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generating official immunization records needed for school or daycare entry; keeping track of 
patients who are overdue for an immunization; and generating reminders to patients who are 
due for immunization. (Every Child By Two Foundation, 2010; Glazner, Beatty, Pearson, & 
et al, 2004) This more efficient handling of vaccine records can have real benefits to 
individual children and whole communities, since more than 25% of children between 19 and 
35 months old are not up to date on immunization, and more than ten percent of children 
between nineteen and 35 months have received at least one extra, unnecessary dose of 
vaccine. (Kolasa et al., 2006) Further, the savings in staff time can also be significant, since 
registries reduce staff time in finding vaccination records at other providers, managing 
vaccine inventory, and consolidating billing information. (Every Child By Two Foundation, 
2010; Glazner et al., 2004) In an analysis of time spent on certain immunization-related 
activities at private practices in Colorado, it was found that time spent per shot on nonroutine 
immunization activities, which includes vaccine management and providing immunization 
records, decreased from 3.1 minutes to 2.3 minutes after implementation and use of a vaccine 
registry.  (Glazner et al., 2004) While the time savings per shot may seem small, if dozens or 
hundreds of shots are given at a practice per day, hours of nursing staff time per day could be 
saved. 
 Consolidation of immunization records from multiple providers has been hailed as 
one of the greatest benefits of an immunization registry. (Glazner et al., 2004; Kempe et al., 
2001; Kolasa et al., 2006; Schauer et al., 2009)  One-fifth of children have been seen by more 
than one provider by the time they are age two (Linkins & Feikema, 1998), necessitating 
communication between providers.  This communication may not be possible at the moment 
when the child presents to the clinic if the provider or parents do not have a complete 
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immunization record.  Instead of spending time trying to piece together a child’s 
immunization record or just giving the child a potential extra dose to be sure, consolidation 
of records via an immunization registry can save time, vaccines, and reduce the chance of 
adverse events by reducing extra immunization. 
 The ability of an immunization registry system to identify patients who are behind in 
vaccinations, due for vaccinations, as well as generate reminder and recall notices for 
patients, has been proven to increase overall vaccination rates (Tickner, Peman, & 
Woodcock, 2006) and well as save time for the practice staff. Generation of data regarding 
vaccination coverage could be facilitated with optimal immunization registry systems that 
have complete current and historical data.  Currently, the National Immunization Survey 
compiles data from paper-based records, a tedious and time-consuming process.  (Khare, 
Picinino, Barker, & Linkins, 2006)  Implementing an automated process based on an 
electronic immunization registry would save time and increase accuracy. 
 
BARRIERS TO IMMUNIZATION REGISTRY ADOPTION 
 Despite the benefits that use of an immunization registry can bring to health care 
practices, patients, and the general population, registry use is still well below Healthy People 
2010 targets of 95% coverage.   Research into providers who do not participate in 
immunization registries shows that financial cost and staff time are the largest barriers to 
entry. (Glazner et al., 2004)   
 The direct cost to a provider for participating in an immunization registry is 
comprised of labor and equipment expenses.   Both cost and accuracy can be affected 
depending on how the data is entered into the registry.  Entry by provider staff, specifically 
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nurses who actually performed the immunizations, led to the highest costs.  Entry into the 
registry by a data entry specialist and automatic transfer from electronic medical records cost 
significantly less.  (Rask, Wells, Kohler, Rust, & Cangialose, 2000) Time spent training to 
use the registry system must also be considered, along with troubleshooting and maintenance 
tasks.  A major barrier to immunization registry adoption is the fact that many providers 
would have to maintain the regular medical record and then manually enter the immunization 
into the registry.  This takes extra time, and may be done at irregular intervals long after the 
shot was given, thereby inhibiting the usefulness of a registry system to provide the most up-
to-date data to providers.  (Rask et al., 2000) Additionally, the cost of necessary equipment, 
such as computers, printers, or internet access must be taken into account if these items are 
not already present at the provider site. 
 Besides direct costs to providers, incomplete immunization registry data result in 
incomplete or inaccurate immunization statistics that can adversely affect larger policy and 
financial decisions.  A 2006 analysis of the city of Philadelphia’s immunization registry 
found that while 92% of the city’s children were entered into the registry, differences in 
documentation of up to eighteen percent were found between registry data and paper records 
for DTaP, polio, MMR, and Hib vaccinations.  (Kolasa et al., 2006) Incomplete data could 
lead to missed immunization opportunities or extra immunizations if the record was not 
properly recorded. 
 Incomplete registry data also means that the National Immunization Survey must rely 
on paper records and random digit dialing surveys to conduct the nation’s immunization 
status survey. (Smith et al., 2005)   However, recent studies have shown that combining 
paper record information with registry data provides a more accurate description of the 
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nation’s true immunization status.  (Khare et al., 2006)  Having a registry system with 
complete data would allow updated immunization status reports to be generated and updated 
quickly, allowing for potential annual or semi-annual immunization statistics, allowing 
public health professionals to quickly target deficient areas or better cope with unexpected 
outbreaks of disease. 
 The true usefulness of an immunization registry cannot be realized if the current 
registries remained isolated from each other.  In a mobile society such as in the United States, 
it is not uncommon to move out of a target area of one immunization registry into the target 
area of another.   Persons who live near state borders may get medical care in more than one 
state.  Sharing information across state lines, however, may require special legislation to 
allow private medical information to be transmitted to out-of-area providers.  The Every 
Child By Two organization and the George Washington University have drafted sample 
legislation for use by public health officials to facilitate passage of data-sharing legislation. 
(Every Child By Two Foundation, 2010) 
 
OVERCOMING BARRIERS TO IMMUNIZATION REGISTRY USE 
 While the barriers to entry for a practice to participate in an immunization registry 
can be high in both cost and logistical issues, and there are current limitations to registry 
usefulness, it is important for providers, patients, and policymakers to realize the importance 
of having functional, accurate immunization registries.  Overcoming these barriers and 
limitations will not have a one-size-fits-all approach; in order to be effective and efficient, 
the solutions must be tailored to the problem. 
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 To ensure both time savings for staff and accuracy when entering data into the 
registry, the method of data entry should be integrated into records systems that the provider 
already uses.  In a review of the city of Boston’s immunization registry, researchers found 
that 59% of records contained at least one error in data entry, and 38% of all errors were 
vaccines that had not been entered into the registry. (Samuels, Appel, Reddy, & Tilson, 
2002)  Whether these errors are due to lack of time to complete data entry at the time of 
immunization, lack of training, or a myriad of other reasons, these errors and the burden of 
duplicating recordkeeping could be eliminated if the immunization registry accepted data 
from a provider’s existing recordkeeping method.   In a survey of Atlanta’s immunization 
registry, a provider with automated data entry had a per shot cost of participating in the 
registry of $0.24, while a provider with manual data entry by clinic nurses had a per shot cost 
of participation of $3.24. (Rask et al., 2000) While some providers may think that the initial 
cost of setting up an automated data interface may be expensive, it would soon become cost 
effective in the long term.  Specifically, saving $3.00 per shot would add up quickly if many 
shots are given per day. Additionally, an automated data interface would also free nurses to 
do more medically-oriented tasks, such as patient education or administering more 
immunizations.  Additionally, allowing the immunization registry data entry to be integrated 
with a provider’s existing recordkeeping method could also automate billing procedures for 
immunizations and vaccine inventory management. 
 One method for increasing usage of immunization registries in a community is to 
involve parents.  Educating parents to the benefits of an immunization registry can help 
recruit a strong ally that could help secure funding or local impetus for creation or further 
action in developing an immunization registry through political activities or lobbying local 
27 
 
policymakers.  In a survey of parents, it was found that they generally believe that 
immunization registry costs should be paid by the government, vaccine companies, or 
insurance companies. (Linkins et al., 2006)  Despite Healthy People 2010 goals of 95% 
immunization registry coverage and increasing uptake of immunization registries nationwide, 
parents are woefully undereducated when it comes to knowledge of their local immunization 
registry.  In a study conducted of parents whose children were enrolled in an immunization 
registry in central New York State, only 29% were aware of the existence of the registry. 
(Callahan, Reed, Meguid, Wojcik, & Reed, 2004) In a survey of parents in four states, fewer 
than ten percent were aware of immunization registries, and among those that were, only 
26.5% had enrolled their children in a registry where active enrollment of children is 
necessary. (Callahan et al., 2004) Interestingly, among parents who chose not to get their 
children vaccinated and were aware of the registry, 65% had enrolled their children in the 
registry. (Linkins et al., 2006) Parents were also generally unaware of legislation regarding 
immunization registries with less than seven percent reporting knowledge of such legislation, 
which could appropriate additional funding for registries and facilitate sharing of data 
between immunization registries in different areas. (Linkins et al., 2006) Educating parents 
about the dangers of vaccine preventable diseases, the ease of obtaining immunization 
records and ensuring that their children receive proper immunization may also be helpful in 
rallying support for immunization registries.  The American Immunization Registry 
Association provides advocacy materials and examples of patient education materials on its 
website (http://www.immregistries.org) (American Immunization Registry Association, 
2010) and many states, including North Carolina, have immunization registry websites.  
(North Carolina Department of Health and Human Services, 2010b) 
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 In order for immunization registries to be truly useful, isolated systems must be 
linked with others and allowed to share data between themselves as well as link with other 
health care databases such as WIC and Medicaid. The Every Child By Two organization has 
drafted legislation (Every Child By Two Foundation, 2010) to help public health officials 
present legislation to their governing bodies that permit sharing of health data between 
systems, which may facilitate integration of or communication between registries in different 
jurisdictions. This inter-database sharing will become increasingly important as more 
Medicaid recipients receive immunizations at private providers, (Linkins & Feikema, 1998) 
and to facilitate registry usefulness for children who move from one registry area to another, 
or receive care in one state but lives in another. 
 Having an immunization registry that is adaptable in various provider settings will 
increase its usefulness and encourage participation.  The CDC has made available several 
open-source registry computing codes, technical protocols, and guides that will facilitate 
future expansion ability, as well as foster compatibility with many other databases as 
possible. (National Center for Immunization and Respiratory Diseases, 2010) Future modules 
that would allow providers to customize their vaccine registry system to meet their individual 
needs while maintaining compatibility with other systems would be helpful. 
 
CONCLUSION 
 With the support of the CDC and the targets set by the Healthy People 2010 goals, 
support for and uptake of immunization registries has risen dramatically throughout the last 
decade.  Immunization registries are present in all 50 states, six major cities, and three United 
States territories.  These registries have been proven to promote healthier children by 
29 
 
reducing extra immunization, ensuring that children receive up-to-date and proper 
immunizations, save medical costs by preventing vaccine-preventable diseases, and save 
providers time and money.   The limitations of immunization registries are being worked 
through, and automating data entry and ensuring communication between different systems 
will be of paramount importance to continue the momentum.   Officials should proactively 
ensure that legislation is in place to facilitate data sharing between systems, and registry 
designers should ensure that the systems are adaptable, expandable, and nationally 
compatible with protocols developed by the CDC.  Parents should be educated and involved 
with all aspects of registry use, as they can be powerful allies.  Finally, steps should be taken 
to ensure that vaccine registries are seamlessly and cost-effectively integrated with providers’ 
existing recordkeeping systems to facilitate implementation, increase compliance, ease data 
entry, and ensure accuracy. 
 We are well on our way to meeting the Healthy People 2010 goal of having 95% of 
children less than six years of age enrolled in an immunization registry.  With these 
registries, we can ensure healthier children, lower provider costs, improve recordkeeping, 
and advance towards a society free of vaccine preventable disease. 
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